Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
The $10.77 purchase price equals the stock’s November 3, 2026 closing price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) entered a securities purchase agreement for a private placement expected to raise approximately $80 million. The company agreed to sell 7,428,040 common shares at $10.77 each, with closing expected on or about November 4, 2026. Gross proceeds exclude placement agent fees and other offering expenses.
Lyell expects the financing to extend its cash runway into 2028, supporting ronde-cel and LYL273 development. For ronde-cel, a cell therapy candidate for relapsed/refractory large B-cell lymphoma, additional PiNACLE trial data are expected in December 2026, the full pivotal dataset in mid-2027 and a biologic drug approval application in the second half of 2027. For LYL273, its cell therapy candidate for metastatic colorectal cancer, Lyell expects additional clinical data and a planned End-of-Phase 1 FDA meeting in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Private placement is expected to raise approximately $80 million in gross proceeds for Lyell. 30% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Financing is expected to extend cash runway into 2028, beyond anticipated clinical and regulatory milestones.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Ronde-cel’s initial biologic drug approval application is expected in the second half of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Ronde-cel development funding supports ongoing pivotal trials and planned regulatory submission activities.
- Minor point. Forward-looking: it has not happened yet and may not happen.PiNACLE clinical updates are expected in December 2026, with the full pivotal dataset anticipated in mid-2027.
4 minor points
- Minor pointRonde-cel has FDA RMAT and Fast Track designations for third-or-later-line relapsed/refractory diffuse large B-cell lymphoma.
- Minor pointRonde-cel also has FDA RMAT designation for second-line large B-cell lymphoma.
- Minor point. Forward-looking: it has not happened yet and may not happen.LYL273 funding supports development toward recommended Phase 2 dose selection and safety management plan optimization.
- Minor point. Forward-looking: it has not happened yet and may not happen.LYL273 additional clinical data and a planned End-of-Phase 1 FDA meeting are expected in 2027.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Issuance of 7,428,040 common shares at $10.77 each will dilute existing shareholders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Placement agent fees and other offering expenses will reduce net proceeds below gross proceeds.
News Explained
If the placement closes, the new shares will reduce existing holders’ percentage ownership; resale registration is a separate step.
Lyell Immunopharma has agreed to sell approximately
The shares are unregistered and may be resold in the United States only under an effective registration statement or an exemption; Lyell has granted investors customary resale Form S-3 registration rights, which provide a route to later registered resale rather than representing a completed sale.
Details
Market move: LYEL +31.38% vs previous close. private placement
On Nov 4, the day this news came out, the latest delayed price for LYEL is 31.38% above the previous close. Argus tracked a peak move of +27.9% during the session. Our momentum scanner has recorded 33 alerts for this stock so far that day. The latest delayed price is $14.15. Relative volume is exceptionally heavy at 37.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Gross proceeds
- Approximately $80 million
- Before placement agent fees and other offering expenses
- Shares to be sold
- 7,428,040 shares
- Common stock private placement
- Purchase price
- $10.77 per share
- Equal to the November 3, 2026 closing price
- Cash runway
- Into 2028
- Expected to include ronde-cel pivotal data and BLA submission, and LYL273 updates
- Pivotal dataset
- Mid-2027
- Ronde-cel PiNACLE trial
- BLA submission
- Second half of 2027
- Ronde-cel submission to the FDA expected after pivotal data
Previous Private placement Reports
-
An additional $50 million tranche brought total placement proceeds to about $100 million and runway into Q2 2027.
-
Agreement for up to $100 million included an initial $50 million closing and milestone-linked additional financing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
private placement financial
car t-cell medical
biologics license application (bla) regulatory
regenerative medicine advanced therapy (rmat) regulatory
fast track designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.
- Ronde-cel, a next-generation CD19/CD20 CAR T-cell product candidate, is advancing toward pivotal data in mid-2027, with the potential to deliver meaningful and durable clinical benefit for patients with relapsed/refractory large B-cell lymphoma
- Proceeds expected to extend cash runway into 2028, beyond anticipated BLA submission for ronde-cel in the second half of 2027, as well as updated clinical data from our GCC-targeted LYL273 program for patients with metastatic colorectal cancer
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately
The financing is expected to extend Lyell’s cash runway into 2028, providing capital to support key clinical and regulatory milestones for rondecabtagene autoleucel (ronde-cel), its next-generation dual-targeting CD19/CD20 CAR T-cell product candidate being developed for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Lyell expects to present additional clinical data from the ongoing pivotal PiNACLE trial in the third-or later-line (3L+) LBCL setting at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026, with the full pivotal dataset anticipated in mid-2027 and submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) expected to follow in the second half of 2027.
“This financing strengthens our financial position and supports the execution of our strategy as we approach several important clinical and regulatory milestones,” said Smital Shah, Chief Financial and Business Officer of Lyell. “We see a significant clinical and commercial opportunity for ronde-cel, which has the potential to deliver durable responses with a one-time treatment that can be administered in the outpatient setting. We are pleased to have the strong support of our syndicate of high-quality existing and new investors as we advance toward these important milestones.”
Ronde-cel is currently being evaluated in two pivotal trials: PiNACLE, a single-arm trial in the 3L+ LBCL setting intended to support an initial BLA submission for regular marketing approval, and PiNACLE-H2H, a Phase 3 randomized controlled trial comparing ronde-cel to investigator’s choice of an approved CD19-directed CAR T-cell therapy in the second-line (2L) setting. Ronde-cel has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for R/R diffuse LBCL in the 3L+ setting, as well as RMAT designation for LBCL in the 2L setting.
Lyell is also advancing LYL273, its GCC-targeted CAR T-cell product candidate for patients with metastatic colorectal cancer (mCRC). The program is progressing toward selection of a recommended Phase 2 dose and optimization of the safety management plan, with additional clinical data and a planned End-of-Phase 1 meeting with the FDA expected in 2027.
Private Placement Details
Under the terms of the securities purchase agreement, Lyell has agreed to sell 7,428,040 shares of common stock at a purchase price of
Goldman Sachs and Leerink Partners acted as placement agents in connection with the financing.
Lyell intends to use the net proceeds from the private placement, together with its existing cash, cash equivalents and marketable securities, to support the continued clinical development of ronde-cel, including its ongoing pivotal trials and planned regulatory submission activities, and the continued development of LYL273, as well as for working capital and other general corporate purposes.
Following the financing, Lyell expects its cash, cash equivalents and marketable securities to be sufficient to meet working capital and capital expenditure needs into 2028, including through the anticipated pivotal data and BLA submission for ronde-cel, as well as through the expected clinical data and regulatory update from the LYL273 development program in mCRC.
The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
The investors have been granted customary resale Form S-3 registration rights for the shares of common stock issued in the financing.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 3,000 CAR T-cell doses per year. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the timing, size, pricing and completion of the proposed private placement; the expected use of proceeds from the private placement; Lyell’s plans for its existing cash, cash equivalents and marketable securities, and its expectation that its financial position and cash runway will be sufficient to meet working capital and capital expenditure needs into 2028; Lyell’s expectations around the progress of the PiNACLE and PiNACLE-H2H trials, including the expected timing for release of additional and pivotal data from the PiNACLE trial; the use of pivotal data from the PiNACLE trial to support a BLA submission to the FDA in the second half of 2027 and other expectations around regulatory submissions; Lyell’s expectations around the progress of the U.S. Phase 1 trial for LYL273, including the expected activities to determine a recommended Phase 2 dose and optimized safety plan and timing for release of additional clinical data from this trial and an End-of-Phase 1 FDA meeting; the anticipated benefits of Orphan Drug, RMAT and Fast Track designations for ronde-cel ; the capability of LyFE to manufacture drug supply through potential commercial launch and its expected manufacturing capacity; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: Lyell operates in a rapidly evolving industry and has a limited operating history; Lyell’s ability to successfully develop, manufacture and commercialize product candidates or its experiencing significant delays in doing so; Lyell’s dependence on the enrollment and retention of patients in its current and planned clinical trials for its product candidates; the potential for results of Lyell’s research, nonclinical studies or earlier clinical trials to not be predictive of future results; clinical development involving a lengthy and expensive process with uncertain outcomes; Lyell’s product candidates and technologies being based on novel technologies that are unproven and may not result in approvable or marketable products; Lyell facing substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than it does; Lyell’s ability to obtain and maintain sufficient intellectual property protection for its product candidates; the complexity of manufacturing cellular therapies; Lyell’s ability to manufacture drug products for its clinical trials itself and any potential delays in further qualifying or in receiving regulatory approvals for any manufacturing facility or product candidates or in expanding its manufacturing capacity; Lyell’s reliance on third parties; implementation of Lyell’s strategic plans for its business and product candidates and Lyell’s realization of the expected benefits of such plans; the potential reduction of Lyell’s cash resources and fluctuations in Lyell’s operating results and financial condition as a result of Lyell’s milestone, royalty and success payment obligations; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, being filed with the Securities and Exchange Commission August 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Lyell Investor Relations
IR@lyell.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Lyell expect ronde-cel pivotal data and an FDA application?
Lyell anticipates the full PiNACLE pivotal dataset in mid-2027 and a Biologics License Application submission in the second half of 2027. Additional clinical data from the ongoing trial are expected at the American Society of Hematology meeting in December 2026.
What are Lyell’s two pivotal ronde-cel trials studying?
PiNACLE studies ronde-cel in third-or-later-line large B-cell lymphoma, while PiNACLE-H2H studies it in the second-line setting. PiNACLE is a single-arm trial intended to support an initial application for regular marketing approval. PiNACLE-H2H is a Phase 3 randomized controlled trial comparing ronde-cel with an investigator-selected approved CD19-directed CAR T-cell therapy.